103 related articles for article (PubMed ID: 31711520)
1. HO-1 promotes resistance to an EZH2 inhibitor through the pRB-E2F pathway: correlation with the progression of myelodysplastic syndrome into acute myeloid leukemia.
He Z; Zhang S; Ma D; Fang Q; Yang L; Shen S; Chen Y; Ren L; Wang J
J Transl Med; 2019 Nov; 17(1):366. PubMed ID: 31711520
[TBL] [Abstract][Full Text] [Related]
2. MEK/ERK and PI3K/AKT pathway inhibitors affect the transformation of myelodysplastic syndrome into acute myeloid leukemia via H3K27me3 methylases and de‑methylases.
Zheng Z; Chen X; Zhang Y; Ren F; Ma Y
Int J Oncol; 2023 Dec; 63(6):. PubMed ID: 37921060
[TBL] [Abstract][Full Text] [Related]
3. EZH2 Promotes Corneal Endothelial Cell Apoptosis by Mediating H3K27me3 and Inhibiting HO-1 Transcription.
Lin Y; Su H; Zou B; Huang M
Curr Eye Res; 2023 Dec; 48(12):1122-1132. PubMed ID: 37800319
[TBL] [Abstract][Full Text] [Related]
4. Vemurafenib induces senescence in acute myeloid leukemia and myelodysplastic syndrome by activating the HIPPO signaling pathway: implications for potential targeted therapy.
Zhou Q; Zhang J; Zhang J; Liang S; Cai D; Xiao H; Zhu Y; Xiang W; Rodrigues-Lima F; Chi J; Guidez F; Wang L
Biol Direct; 2024 Jan; 19(1):6. PubMed ID: 38178263
[TBL] [Abstract][Full Text] [Related]
5. SHP-2 and PTP-pest induction during Rb-E2F associated apoptosis.
Morales LD; Pena K; Kim DJ; Lieman JH
Cell Mol Biol Lett; 2012 Sep; 17(3):422-32. PubMed ID: 22644489
[TBL] [Abstract][Full Text] [Related]
6. p53 immunohistochemistry as an ancillary tool for rapid assessment of residual disease in TP53-mutated acute myeloid leukemia and myelodysplastic syndromes.
Brar N; Lawrence L; Fung E; Zehnder JL; Greenberg PL; Mannis GN; Zhang TY; Gratzinger D; Oak J; Silva O; Kurzer J; Tan B; Menke JR; Fernandez-Pol S
Am J Clin Pathol; 2024 Apr; ():. PubMed ID: 38643353
[TBL] [Abstract][Full Text] [Related]
7. The development of pevonedistat in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): hope or hype?
Snow A; Zeidner JF
Ther Adv Hematol; 2022; 13():20406207221112899. PubMed ID: 35898435
[TBL] [Abstract][Full Text] [Related]
8. pRB, a tumor suppressor with a stabilizing presence.
Manning AL; Dyson NJ
Trends Cell Biol; 2011 Aug; 21(8):433-41. PubMed ID: 21664133
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic vulnerabilities of leukemia harboring inactivating EZH2 mutations.
Alqazzaz MA; Luciani GM; Vu V; Machado RAC; Szewczyk MM; Adamson EC; Cheon S; Li F; Arrowsmith CH; Minden MD; Barsyte-Lovejoy D
Exp Hematol; 2024 Feb; 130():104135. PubMed ID: 38072134
[TBL] [Abstract][Full Text] [Related]
10. Lymph node myeloid sarcoma with TP53‑associated myelodysplastic syndrome: A case report.
Mao M; Deng S
Oncol Lett; 2024 Jul; 28(1):324. PubMed ID: 38807682
[TBL] [Abstract][Full Text] [Related]
11. Development of MDS in Pediatric Patients with GATA2 Deficiency: Increased Histone Trimethylation and Deregulated Apoptosis as Potential Drivers of Transformation.
Schreiber F; Piontek G; Schneider-Kimoto Y; Schwarz-Furlan S; De Vito R; Locatelli F; Gengler C; Yoshimi A; Jung A; Klauschen F; Niemeyer CM; Erlacher M; Rudelius M
Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067298
[TBL] [Abstract][Full Text] [Related]
12. Multiplex imaging reveals spatially resolved DNA-damage response neighborhoods in TP53-mutated myelodysplastic neoplasms.
Yeung T; Zhang Y; Kennedy B; Walsh C; Love T; Xia D; Bhattacharya A; Krishnan RG; Head D; Burack R
J Pathol; 2024 Jul; 263(3):386-395. PubMed ID: 38801208
[TBL] [Abstract][Full Text] [Related]
13. Attenuated cell cycle and DNA damage response transcriptome signatures and overrepresented cell adhesion processes imply accelerated progression in patients with lower-risk myelodysplastic neoplasms.
Kaisrlikova M; Kundrat D; Koralkova P; Trsova I; Lenertova Z; Votavova H; Merkerova MD; Krejcik Z; Vesela J; Vostry M; Simeckova R; Markova MS; Lauermannova M; Jonasova A; Cermak J; Divoky V; Belickova M
Int J Cancer; 2024 May; 154(9):1652-1668. PubMed ID: 38180088
[TBL] [Abstract][Full Text] [Related]
14. pRb-E2F signaling in life of mesenchymal stem cells: Cell cycle, cell fate, and cell differentiation.
Popov B; Petrov N
Genes Dis; 2014 Dec; 1(2):174-187. PubMed ID: 30258863
[TBL] [Abstract][Full Text] [Related]
15. Analyzing Blood Cells of High-Risk Myelodysplastic Syndrome Patients Using Interferometric Phase Microscopy and Fluorescent Flow Cytometry.
Barnea I; Luria L; Girsault A; Dabah O; Dudaie M; Mirsky SK; Merkel D; Shaked NT
Bioengineering (Basel); 2024 Mar; 11(3):. PubMed ID: 38534530
[TBL] [Abstract][Full Text] [Related]
16. Retracted: lncRNA HOTTIP Recruits EZH2 to Inhibit PTEN Expression and Participates in IM Resistance in Chronic Myeloid Leukemia.
International SC
Stem Cells Int; 2023; 2023():9760693. PubMed ID: 37829611
[TBL] [Abstract][Full Text] [Related]
17. Retracted: Clinical Significance of EZH2 in Acute Myeloid Leukemia.
Intelligence And Neuroscience C
Comput Intell Neurosci; 2023; 2023():9761597. PubMed ID: 37800055
[TBL] [Abstract][Full Text] [Related]
18. M2 Polarization May Contribute to Formation of Granulomatous Dermatitis in Progression of Myelodysplastic Syndrome to Acute Myeloid Leukemia.
Fang WC; Du JS; Su YC; Chiu LW; Yang TT
Dermatol Pract Concept; 2023 Oct; 13(4):. PubMed ID: 37992346
[No Abstract] [Full Text] [Related]
19. CD64-targeted HO-1 RNA interference enhances chemosensitivity in orthotopic model of acute myeloid leukemia and patient-derived bone marrow cells.
Yong SB; Chung JY; Kim SS; Choi HS; Kim YH
Biomaterials; 2020 Feb; 230():119651. PubMed ID: 31787334
[TBL] [Abstract][Full Text] [Related]
20. Ivacaftor attenuates gentamicin-induced ototoxicity through the CFTR-Nrf2-HO1/NQO1 pathway.
Hu R; Wu F; Zheng YQ
Redox Rep; 2024 Dec; 29(1):2332038. PubMed ID: 38563333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
